Wolfgang E. Schmidt - Concepedia

Author

Wolfgang E. Schmidt

Also Known As

Chronik, Cornelis De Vos, Franz Mutscheller, K. Hellwig, L. Füzesi, Stefan Schlabe, Stubbe, H., W E SCHMIDT, W E Schmidt, W SCHMIDT

415

Publications

17.8K

Citations

H-Index

211

Concepts

All Affiliations

St. Josef-Hospital Ruhr University Bochum Christian-Albrechts-Universität zu Kiel University of Göttingen University of Copenhagen

About

Wolfgang E. Schmidt is an author at St. Josef-Hospital specializing in medicine, pharmacology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	51	112	10K
2	Health Sciences	18	19	1.8K
3	Natural Sciences	10	10	370
4	Social Sciences	3	3	109
5	Public Health	1	1	86

Wolfgang E. Schmidt

199

Publications

16.5K

Citations

H-Index

Page 1

	Year	Citations
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) John B. Buse, Julio Rosenstock, Giorgio Sesti, The Lancet Open-label TrialDiabetes ManagementMedicineDiabetesClinical Trials	2009	1.5K
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum Rolf Mentlein, Baptist Gallwitz, Wolfgang E. Schmidt European Journal of Biochemistry	1993	1.2K
Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin Thomas Berg, Michael Wagner, Samer Nasser, Gastroenterology Peginterferon-alfa-2a Plus RibavirinHepatologyHepatitis CVersus 72Viral Hepatitis	2006	519
Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes Juris J. Meier, Baptist Gallwitz, Stefan Salmen, The Journal of Clinical Endocrinology & Metabolism	2003	367
Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance Kirsten Vollmer, Jens J. Holst, Birgit Baller, Diabetes	2007	352
Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects Juris J. Meier, Michael A. Nauck, Daniel Kranz, Diabetes	2004	327
Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets Wolfgang E. Schmidt, E. G. Siegel, W. Creutzfeldt Diabetologia Signal TransductionBiochemistryMedicinePhysiologyDiabetes	1985	315
Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia Juris J. Meier, Baptist Gallwitz, Nina Siepmann, Diabetologia Metabolic SyndromeHealth SciencesMedicineDiabetesPhysiology	2003	312
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans Juris J. Meier, Arnica Gethmann, Oliver Götze, Diabetologia Metabolic SyndromeNon-esterified Fatty AcidsBiochemistryGlucagon-like Peptide 1Medicine	2006	268

Page 1